glp-1 bone loss Effects of Glucagon-Like Peptide-1 receptor agonists on health in people living with obesity | Osteoporosis International GLP-1 and GIP: Magic bullet

Personalized care, built around you A lower-dose GLP-1 approach is often chosen by patients seeking a more gradual, personalized path to metabolic balance and appetite regulation

It helps with weight loss and supports metabolic health, making it ideal for those with a BMI of 30 or higher, or a BMI of 27 with obesity-related conditions like high blood pressure, high cholesterol, prediabetes, or type 2 diabetes

While 2.4 mg is the FDA-approved maintenance dose for semaglutide, not everyone needs the absolute max to achieve substantial weight loss

But GLP-1s also come with some tricky-to-manage side effects

The FDA's move is bad news for manufacturers of compounded semaglutide and the telehealth companies that have built up a market selling cheaper alternatives to branded weight loss drugs

J.ThompsonV